Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, reported unaudited financial results for the third quarter ended Dec. 31, 2025, emphasizing continued progress across its key clinical programs. The company ended the quarter with $195.1 million in cash and reported a net loss of $42.7 million, as operating expenses increased to support advancing clinical activities. Management highlighted the strengthened balance sheet, expanding intellectual property portfolio, and upcoming clinical data milestones in 2026.
The company is advancing HLP003, a proprietary novel serotonergic agonist (NSA), in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 development for generalized anxiety disorder. Helus Pharma also has an extensive research portfolio of investigational NSAs.
Helus Pharma completed a leadership transition and corporate rebranding during the quarter. The company, formerly known as Cybin Inc., operates under the commercial name Helus Pharma. The company is committed to developing synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, aiming to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
For more details, the full press release is available at https://ibn.fm/VigPf. For company updates, visit www.helus.com or follow the team on social media. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
Helus Pharma’s progress is significant as it moves closer to potentially offering new treatment options for major depressive disorder and generalized anxiety disorder, conditions with substantial unmet medical needs. The Phase 3 data for HLP003, expected in 2026, will be a critical milestone for the company and the field.
